Lilly Again Sues APP Over Generic Alimta

Law360, New York (July 18, 2011, 8:10 PM EDT) -- Eli Lilly & Co. and the trustees of Princeton University sued APP Pharmaceuticals LLC on Friday in Delaware in another attempt to stop the drugmaker from producing a generic version of chemotherapy drug Alimta.

The suit accuses APP of infringing the patent covering Alimta, U.S. Patent Number 5,344,932, when the pharmaceutical company filed an application with the U.S. Food and Drug Administration seeking approval for a 100-milligram dose of a generic version of Alimta.

The complaint is the second suit brought by Lilly and Princeton against...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.